This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK (
TheStreet) -- The
Federal Reserve is not going to get in the way of a good holiday season, Jim Cramer told his
"Mad Money" viewers Friday.
That's why Cramer said he'd use any weakness in the market next Wednesday to buy up some of the great stocks that will be put on sale.
Cramer expects the market to weaken on Wednesday ahead of of Thankgiving as it digests the latest unemployment data, durable goods and consumer sentiment numbers. That would be a great time to buy some of the stocks that will be reporting earlier next week, such as
Palo Alto Networks(PANW), both of which report on Monday.
Cramer said the highly valued Workday could get crushed on anything less that a "beat and raise" quarter, but this cloud-based human resource management company is a buy on any weakness. Palo Alto, he said, is also highly valued, but also worth the expense.
Tuesday brings earnings from
Hewlett-Packard(HPQ), a stock Cramer said he's liking more now that
Dell has none private. He also expects solid results from
Cracker Barrel(CBRL) and
DSW(DSW), three stocks that are up 41%, 41% and 81% respectively for the year.
Also on Tuesday,
TiVo(TIVO), a stock that's also become a great value.
Cramer said he'd use weakness on Wednesday to picking any of these names.
Riding High Again
The four horsemen of biotech ride again, Cramer told viewers. The stocks of
Gilead Sciences(GILD - Get Report),
Celgene(CELG - Get Report),
Biogen Idec(BIIB - Get Report) and
Regeneron(REGN - Get Report) will be the anointed four going into the close of the year.
Cramer said love for the biotechs comes and goes, fizzling late this summer after a rash of red-hot IPOs. But over the past few weeks, the biotechs have once again come into fashion and been red-hot commodities for investors.
Cramer said there's three reasons for the move. First is the continued economic growth, followed by growth overseas and, finally, a host of new drug approvals. All three of these factors will continue these stocks on their current trajectory. Both Gilead and Celgene have seen approvals in the European Union strengthen their stocks while Biogen saw its shares jump $20 just today on a new approval.